Artiva Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARTV research report →
Range $4 – $4
Price Chart
About the company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
- CEO
- Fred Aslan
- IPO
- 2024
- Employees
- 134
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ARTV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $186.85M
- P/E
- -1.26
- PEG
- -0.11
- P/S
- 0.00
- P/B
- 0.60
- EV/EBITDA
- -1.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -45.32%
- ROIC
- -31.89%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-2,597,000-1134.7%
- Op Income
- $-90,610,000
- Net Income
- $-83,865,000-43.4%
- EPS
- $-3.43+34.0%
- OCF Growth
- -39.5%
- FCF Growth
- -42.5%
- 52W High
- $14.53
- 52W Low
- $2.96
- 50D MA
- $5.97
- 200D MA
- $8.00
- Beta
- 2.41
- RSI (14)
- 22
- Avg Volume
- 792.26K
No earnings-call transcripts are available for ARTV yet.
- Free Float
- 40.8%
- Shares Outstanding
- 49.43M
- Float Shares
- 20.15M
of shares held by institutions
74 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 18.49M | ▲ 533.65K |
| Viking Global Investors LP | 2.60M | 0 |
| Blackstone Inc. | 2.40M | 0 |
| 5am Venture Management, LLC | 2.35M | 0 |
| Venrock Adviser, LLC | 2.04M | 0 |
| Franklin Templeton Inc | 2.04M | ▲ 43.78K |
| Blackrock, Inc. | 1.51M | ▲ 816.54K |
| Caligan Partners LP | 1.48M | ▼ 255.07K |
| Samsara Biocapital, LLC | 954.86K | 0 |
| Vanguard Capital Management LLC | 942.37K | ▼ 39.45K |
| Propel Bio Management, LLC | 696.44K | 0 |
| Geode Capital Management, LLC | 532.39K | ▲ 178.54K |
Held by 97 ETFs
Biggest fund positions in ARTV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Miralles Gines Diego | sell | 1,043 |
| Nov 17, 26 | Horan Christopher | sell | 20,546 |
| Nov 17, 26 | Bush Jennifer | sell | 19,217 |
| Nov 17, 26 | Banerjee Subhashis | sell | 4,037 |
| Nov 17, 26 | Aslan Fred | sell | 119,771 |
| Nov 2, 26 | Horan Christopher | sell | 10,423 |
| Nov 2, 26 | Bush Jennifer | sell | 8,439 |
| Nov 2, 26 | Banerjee Subhashis | sell | 1,110 |
| Nov 2, 26 | Aslan Fred | sell | 62,178 |
| Oct 6, 26 | Aslan Fred | sell | 23,463 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARTV coverage
Recent articles, reports, and earnings notes.
No research on ARTV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARTV report →INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
prnewswire.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Artiva Biotherapeutics, Inc. – ARTV
globenewswire.com · Nov 17
ARTV Investors Have Opportunity to Join Artiva Biotherapeutics, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
prnewswire.com · Nov 12
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
benzinga.com · Oct 27
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
globenewswire.com · Oct 27
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
globenewswire.com · Oct 2
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
globenewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.